168 related articles for article (PubMed ID: 23193072)
1. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.
Cunha LL; Marcello MA; Morari EC; Nonogaki S; Conte FF; Gerhard R; Soares FA; Vassallo J; Ward LS
Endocr Relat Cancer; 2013 Feb; 20(1):103-10. PubMed ID: 23193072
[TBL] [Abstract][Full Text] [Related]
2. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
3. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
4. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
[TBL] [Abstract][Full Text] [Related]
5. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma.
Cunha LL; Morari EC; Guihen AC; Razolli D; Gerhard R; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2012 Dec; 77(6):918-25. PubMed ID: 22738343
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
7. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
8. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.
Cheng S; Liu W; Mercado M; Ezzat S; Asa SL
Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683
[TBL] [Abstract][Full Text] [Related]
9. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma.
Wagner PL; Moo TA; Arora N; Liu YF; Zarnegar R; Scognamiglio T; Fahey TJ
Ann Surg Oncol; 2008 Oct; 15(10):2833-41. PubMed ID: 18696160
[TBL] [Abstract][Full Text] [Related]
10. Association of CD1a-positive dendritic cells with papillary thyroid carcinoma in thyroid fine-needle aspirations: a cytologic and immunocytochemical evaluation.
Pusztaszeri MP; Sadow PM; Faquin WC
Cancer Cytopathol; 2013 Apr; 121(4):206-13. PubMed ID: 23042745
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8.
Fang W; Ye L; Shen L; Cai J; Huang F; Wei Q; Fei X; Chen X; Guan H; Wang W; Li X; Ning G
Carcinogenesis; 2014 Aug; 35(8):1780-7. PubMed ID: 24608042
[TBL] [Abstract][Full Text] [Related]
12. CD82, and CD63 in thyroid cancer.
Chen Z; Mustafa T; Trojanowicz B; Brauckhoff M; Gimm O; Schmutzler C; Köhrle J; Holzhausen HJ; Kehlen A; Klonisch T; Finke R; Dralle H; Hoang-Vu C
Int J Mol Med; 2004 Oct; 14(4):517-27. PubMed ID: 15375577
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
Sancho M; Vieira JM; Casalou C; Mesquita M; Pereira T; Cavaco BM; Dias S; Leite V
J Endocrinol; 2006 Oct; 191(1):229-38. PubMed ID: 17065406
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles in thyroid carcinomas.
Takano T; Hasegawa Y; Matsuzuka F; Miyauchi A; Yoshida H; Higashiyama T; Kuma K; Amino N
Br J Cancer; 2000 Dec; 83(11):1495-502. PubMed ID: 11076659
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
17. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features.
Knoll MR; Schwab M; Oestreich K; Rumstadt B; Hagmüller E
J Exp Clin Cancer Res; 1997 Jun; 16(2):177-82. PubMed ID: 9261744
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
19. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas.
Puppin C; Fabbro D; Dima M; Di Loreto C; Puxeddu E; Filetti S; Russo D; Damante G
J Endocrinol; 2008 May; 197(2):401-8. PubMed ID: 18434370
[TBL] [Abstract][Full Text] [Related]
20. Expression of telomerase genes in thyroid carcinoma.
Hoang-Vu C; Boltze C; Gimm O; Poremba C; Dockhorn-Dworniczak B; Köhrle J; Rath FW; Dralle H
Int J Oncol; 2002 Aug; 21(2):265-72. PubMed ID: 12118320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
